<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management and outcome of sepsis in term and late preterm neonates</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management and outcome of sepsis in term and late preterm neonates</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management and outcome of sepsis in term and late preterm neonates</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph B Cantey, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen M Puopolo, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sepsis is an important cause of morbidity and mortality among newborn infants. Although the incidence of sepsis in term and late preterm neonates is low, the potential for serious adverse outcomes, including death, is of such great consequence that caregivers should have a low threshold for evaluation and treatment for possible sepsis in neonates. </p><p>The treatment and outcome of bacterial sepsis in term and late preterm neonates will be reviewed here. The epidemiology, clinical features, diagnosis, and evaluation of bacterial sepsis in term and late preterm neonates are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>.)</p><p>Other related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis in preterm neonates (see  <a class="medical medical_review" href="/z/d/html/88740.html" rel="external">"Clinical features and diagnosis of bacterial sepsis in preterm infants &lt;34 weeks gestation"</a> and  <a class="medical medical_review" href="/z/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Group B streptococcal (GBS) infection in neonates and infants, including management of well-appearing newborns at risk for GBS (see  <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants"</a> and  <a class="medical medical_review" href="/z/d/html/5981.html" rel="external">"Management of neonates at risk for early-onset group B streptococcal infection"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Outpatient evaluation and management of febrile neonates (see  <a class="medical medical_review" href="/z/d/html/134347.html" rel="external">"The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation and management of ill-appearing infants (see  <a class="medical medical_review" href="/z/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)"</a>)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The following terms will be used throughout this discussion on neonatal sepsis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Term neonates</strong> are those born at a gestational age of 37 weeks or greater.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late preterm neonates</strong> (also called near-term neonates) are those born from 34 through 36 completed weeks of gestation [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/5034.html" rel="external">"Late preterm infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal sepsis</strong> is a clinical syndrome in an infant 28 days of life or younger, manifested by systemic signs of infection and isolation of a bacterial pathogen from the bloodstream. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1">Sepsis is classified according to the neonate's age at the onset of symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early</strong>-<strong>onset sepsis</strong> is defined as the onset of symptoms before 72 hours of age [<a href="#rid2">2-4</a>], although some experts extend the definition to infections occurring within the first seven days after birth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Late</strong>-<strong>onset sepsis</strong> is generally defined as the onset of symptoms at ≥72 hours of age [<a href="#rid3">3</a>]. Similar to early-onset sepsis, there is variability in its definition, ranging from an onset at &gt;72 hours of life to ≥7 days of age.</p><p></p><p class="bulletIndent1">Newborn infants with early-onset sepsis typically present with symptoms during their birth hospitalization. Term neonates with late-onset sepsis generally present to the outpatient setting or emergency department unless comorbid conditions have prolonged the birth hospitalization. The approach to the evaluation and initial management of febrile neonates in the outpatient setting is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/134347.html" rel="external">"The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management", section on 'Neonates 8 to 21 days old'</a>.)</p><p></p><p class="headingAnchor" id="H341853"><span class="h1">SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>Symptomatic neonates should be treated in a care setting with full cardiopulmonary monitoring and support because the clinical course of these neonates can deteriorate rapidly. Although there are no data demonstrating the importance of supportive care measures in neonates with sepsis, it is generally accepted that the following supportive measures are critical components of management:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintaining adequate oxygenation and perfusion (see  <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">"Respiratory support, oxygen delivery, and oxygen monitoring in the newborn"</a> and  <a class="medical medical_review" href="/z/d/html/126605.html" rel="external">"Neonatal shock: Management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of hypoglycemia and metabolic acidosis (see  <a class="medical medical_review" href="/z/d/html/101425.html" rel="external">"Management and outcome of neonatal hypoglycemia"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance of normal fluid and electrolyte status (see  <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a>)</p><p></p><p>Severely ill patients may require ventilatory, volume, and/or vasopressor support to maintain adequate oxygenation and perfusion. (See  <a class="medical medical_review" href="/z/d/html/5032.html" rel="external">"Overview of mechanical ventilation in neonates"</a> and  <a class="medical medical_review" href="/z/d/html/5039.html" rel="external">"Neonatal shock: Etiology, clinical manifestations, and evaluation"</a>.)</p><p class="headingAnchor" id="H943510014"><span class="h1">ONGOING DIAGNOSTIC EVALUATION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other diagnostic considerations</strong> – In neonates with suspected sepsis, additional testing for other conditions may be warranted based on clinical signs and symptoms. Signs and symptoms of neonatal sepsis are often nonspecific, as summarized in the table  (<a class="graphic graphic_table graphicRef100409" href="/z/d/graphic/100409.html" rel="external">table 1</a>). It may be difficult to differentiate neonatal sepsis from other diseases; however, given the morbidity and mortality of neonatal sepsis, empiric antibiotic therapy should be provided (after cultures are obtained) to neonates with suspected sepsis, pending definitive culture-based diagnosis. Alternative diagnoses should be entertained when a neonate with suspected sepsis has negative cultures. The differential diagnosis is summarized in the table  (<a class="graphic graphic_table graphicRef100409" href="/z/d/graphic/100409.html" rel="external">table 1</a>) and discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lumbar puncture</strong> – If not done during the initial evaluation, a lumbar puncture should be performed in neonates with culture-proven or culture-negative clinical sepsis, whenever possible. Clinical signs suggesting meningitis can be lacking. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Lumbar puncture'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">ANTIBIOTIC THERAPY</span><span class="headingEndMark"> — </span>Neonates with clinical signs of sepsis  (<a class="graphic graphic_table graphicRef72985" href="/z/d/graphic/72985.html" rel="external">table 2</a>) require prompt evaluation and initiation of antibiotic therapy [<a href="#rid2">2,5</a>]. Because the signs and symptoms of sepsis are subtle and nonspecific, the threshold for evaluation and empiric treatment is low. The evaluation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Evaluation and initial management'</a>.)</p><p>The approach discussed in the following sections is generally consistent with guidelines published by the American Academy of Pediatrics and the Centers for Disease Control and Prevention [<a href="#rid2">2,6</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H943509421"><span class="h2">Whom to treat</span><span class="headingEndMark"> — </span>The decision to start antibiotic therapy is based on assessment of risk factors, clinical evaluation, and laboratory tests. Indications for empiric antibiotic therapy include (see  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Evaluation and initial management'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Ill appearance (see  <a class="medical medical_review" href="/z/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerning symptoms, including temperature instability or respiratory, cardiocirculatory, or neurologic symptoms (see  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Clinical manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High estimated risk of early-onset sepsis (EOS) based on a validated risk <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fneonatalsepsiscalculator.kaiserpermanente.org%2F&amp;token=onMkmNxqZshoDc22JN8OR%2BQKCg7t0pcaNNq2h8esYG515dR4JaAxDq9tt4oaRDV5Qc%2FbUukpm4cZ872Q8bCopQ%3D%3D&amp;TOPIC_ID=5046" target="_blank">calculator</a> (see  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Early-onset sepsis calculator'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrospinal fluid (CSF) pleocytosis (white blood cell count of &gt;20 to 30 cells/microL)  (<a class="graphic graphic_table graphicRef54464" href="/z/d/graphic/54464.html" rel="external">table 3</a>) (see  <a class="medical medical_review" href="/z/d/html/6005.html" rel="external">"Bacterial meningitis in the neonate: Clinical features and diagnosis", section on 'Interpretation of cerebrospinal fluid'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive blood, urine, or CSF culture (see  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Blood culture'</a>)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Initial empiric therapy</span><span class="headingEndMark"> — </span>The initial choice of parenteral antimicrobials for suspected sepsis depend on the neonate's age, likely pathogens, susceptibility patterns of organisms in a particular nursery, and presence of an apparent source of infection (eg, skin, joint, or bone involvement)  (<a class="graphic graphic_table graphicRef102574" href="/z/d/graphic/102574.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H5"><span class="h3">Early-onset sepsis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred empiric regimen</strong> – Our suggested empiric regimen for suspected early-onset sepsis (ie, age &lt;72 hours) consists of <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> plus an aminoglycoside. The choice of aminoglycoside depends upon local antibiotic susceptibility patterns. <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">Gentamicin</a> is the usual choice; however, <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a> is preferred in centers with a high prevalence of gentamicin resistance among gram-negative isolates. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – For term and late preterm newborns &lt;72 hours old, our suggested dosing for these agents is as follows [<a href="#rid7">7</a>]. However, dosing regimens may vary by institution.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">Ampicillin</a> is initially given at a dose of 100 mg/kg per dose intravenously (IV) every eight hours; once meningitis is excluded (on the basis of cerebrospinal fluid [CSF] parameters), the dose is reduced to 50 mg/kg per dose IV every eight hours. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">Gentamicin</a> 4 mg/kg per dose IV every 24 hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">Amikacin</a> 15 mg/kg per dose IV every 24 hours or 10 mg/kg per dose IV every 12 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – We generally obtain baseline renal function tests (ie, blood urea nitrogen [BUN] and creatinine levels) at the initiation of aminoglycoside therapy. Serum <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> or <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a> levels are <strong>not</strong> required if a treatment course of ≤48 hours is anticipated and renal function is normal; however, levels should be obtained in neonates receiving a full course of gentamicin or amikacin therapy [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale and supporting evidence</strong> – The combination of <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> and an aminoglycoside is effective in treating most common pathogens that cause early-onset sepsis, including group B <em>Streptococcus</em> (GBS), <em>Listeria</em>, <em>Enterococcus</em>, and most isolates of <em>Escherichia</em> <em>coli</em>  (<a class="graphic graphic_table graphicRef61061" href="/z/d/graphic/61061.html" rel="external">table 5</a>) [<a href="#rid2">2,10</a>]. However, local antibiotic susceptibility patterns should also be considered.</p><p></p><p class="bulletIndent1">In the available studies from the contemporary era, &gt;90 percent of isolates from culture-proven, early-onset neonatal sepsis were susceptible to <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a>, <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a>, or both [<a href="#rid11">11-14</a>].</p><p></p><p class="bulletIndent1">The regimen of <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> plus an aminoglycoside is preferred over ampicillin plus a third or fourth-generation cephalosporin based upon the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The regimen of <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> and a third-generation cephalosporin is not more effective than the combination of ampicillin and an aminoglycoside [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The emergence of cephalosporin-resistant gram-negative organisms (eg, <em>Enterobacter</em> <em>cloacae</em>, <em>Klebsiella</em>, and <em>Serratia</em> species) can occur when cephalosporins are used routinely [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">Ampicillin</a> and aminoglycosides are synergistic in treating infections caused by GBS and <em>Listeria</em> <em>monocytogenes</em>. Cephalosporins are <strong>not</strong> active against <em>L</em>. <em>monocytogenes</em>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a large cohort study, treatment with <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> plus <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> was associated with lower mortality compared with ampicillin plus <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> (1.9 versus 4.2 percent, respectively) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">Ceftriaxone</a> displaces bilirubin from albumin, which may increase the risk of acute bilirubin neurotoxicity [<a href="#rid17">17,18</a>]. Thus, ceftriaxone should not be used in neonates with clinically significant hyperbilirubinemia. If a cephalosporin is used in the treatment regimen, agents other than ceftriaxone are generally preferred (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> [where available], <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>, or <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of expanded-spectrum cephalosporins</strong> – An expanded-spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> [where available], <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>, or <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>) should be added to the regimen for neonates with any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Critical illness</p><p class="bulletIndent2"><span class="glyph">•</span>Risk factors associated with <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> resistance (ie, maternal colonization with multidrug-resistant organisms and/or prolonged antenatal maternal ampicillin treatment)</p><p class="bulletIndent2"><span class="glyph">•</span>Suspected meningitis (see <a class="local">'Coverage for focal sources of infection'</a> below)</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Late-onset sepsis</span><span class="headingEndMark"> — </span>The choice of empiric therapy for late-onset sepsis (age ≥72 hours) depends upon whether the neonate is admitted from the community and thus is at lower risk for infection caused by resistant pathogens or is hospitalized since birth and thus at a higher risk.</p><p class="headingAnchor" id="H943509792"><span class="h4">Admitted from the community</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric regimen</strong> – Acceptable empiric regimens for late-onset sepsis without an apparent focus of infection in neonates admitted from the community include  (<a class="graphic graphic_table graphicRef102574" href="/z/d/graphic/102574.html" rel="external">table 4</a>) [<a href="#rid3">3,19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">Ampicillin</a> plus an aminoglycoside (<a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> or <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a>), or </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">Ampicillin</a> plus an expanded-spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> [if available], <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>, or <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>) </p><p></p><p class="bulletIndent1">The preferred regimen is generally <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> plus an aminoglycoside; however, local antibiotic resistance patterns must be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Dosing depends on postnatal age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For newborns 3 to ≤7 days old [<a href="#rid3">3,7,9,20</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">Ampicillin</a> is initially given at a dose of 100 mg/kg per dose IV every eight hours; once meningitis is excluded (on the basis of CSF parameters), the dose is reduced to 50 mg/kg per dose IV every eight hours </p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">Gentamicin</a> 4 mg/kg per dose IV every 24 hours </p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">Amikacin</a> 15 mg/kg per dose IV every 24 hours or 10 mg/kg per dose IV every 12 hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For newborns &gt;7 days old [<a href="#rid3">3,7,9,20</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">Ampicillin</a> is initially given at a dose of 75 mg/kg per dose IV every six hours; once meningitis is excluded (on the basis of CSF parameters), the dose is reduced to 50 mg/kg per dose IV every eight hours </p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">Gentamicin</a> 5 mg/kg per dose IV every 24 hours</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">Amikacin</a> 18 mg/kg per dose IV every 24 hours or 10 mg/kg per dose IV every eight hours</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring </strong>– We generally obtain baseline BUN and creatinine levels at the initiation of treatment with aminoglycosides. Serum <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> or <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a> levels are <strong>not</strong> required if a treatment course of ≤48 hours is anticipated and renal function is normal; however, levels should be obtained in neonates receiving a full course of gentamicin or amikacin therapy [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale and supporting evidence</strong> – The combination of <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> plus an aminoglycoside or ampicillin plus an expanded-spectrum cephalosporin is effective in treating the most common pathogens that cause late-onset sepsis in term neonates, including most isolates of <em>E. coli</em>, GBS, <em>Listeria</em>, and <em>Enterococcus</em>  (<a class="graphic graphic_table graphicRef61061" href="/z/d/graphic/61061.html" rel="external">table 5</a>) [<a href="#rid11">11</a>]. However, local antibiotic susceptibility patterns should also be considered. The available limited clinical trial data comparing different antibiotic regimens for late-onset neonatal sepsis have not demonstrated any convincing superiority of one regimen over others [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of expanded-spectrum cephalosporins</strong> – An expanded-spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> [where available], <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>, or <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>) should be included in the empiric regimen for critically ill neonates and those with suspected meningitis. (See <a class="local">'Coverage for focal sources of infection'</a> below.)</p><p></p><p class="headingAnchor" id="H943509801"><span class="h4">Hospitalized since birth</span><span class="headingEndMark"> — </span>Neonates who continue to be hospitalized since birth are at higher risk for resistant organisms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric regimen</strong> – Our suggested empiric regimen for suspected hospital-acquired late-onset sepsis (ie, age ≥72 hours) consists of <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> plus an aminoglycoside  (<a class="graphic graphic_table graphicRef102574" href="/z/d/graphic/102574.html" rel="external">table 4</a>). The choice of aminoglycoside depends upon local antibiotic susceptibility patterns. <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">Gentamicin</a> is the usual choice; however, <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a> is preferred in centers with a high prevalence of gentamicin resistance among gram-negative isolates. </p><p></p><p class="bulletIndent1">In centers that routinely screen for methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) colonization, a semisynthetic penicillin (eg, <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> or <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a>) can be substituted for <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> if the neonate is not critically ill and the MRSA screen is negative. Semisynthetic penicillins are superior to vancomycin for the treatment of methicillin-susceptible <em>S. aureus</em> (MSSA) [<a href="#rid22">22</a>]. However, vancomycin should be included in the empiric regimen for neonates who are MRSA-colonized and/or critically ill at presentation [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vancomycin</strong> – Weight-based <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> dosing regimens for term and late preterm neonates vary somewhat between institutions. Two common approaches include dosing according to serum creatinine (Scr) and dosing according to postmenstrual age (PMA).</p><p></p><p class="bulletIndent2">For dosing based upon Scr, the initial IV loading is 20 mg/kg; subsequent maintenance dosing according to Scr is as follows [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Scr &lt;0.7 mg/dL – 15 mg/kg per dose IV every 12 hours</p><p class="bulletIndent3"><span class="glyph">-</span>Scr 0.7 to 0.9 mg/dL – 20 mg/kg per dose IV every 24 hours</p><p class="bulletIndent3"><span class="glyph">-</span>Scr 1 to 1.2 mg/dL – 15 mg/kg per dose IV every 24 hours</p><p class="bulletIndent3"><span class="glyph">-</span>Scr 1.3 to 1.6 mg/dL – 10 mg/kg per dose IV every 24 hours</p><p class="bulletIndent3"><span class="glyph">-</span>Scr &gt;1.6 mg/dL – 15 mg/kg per dose IV every 48 hours</p><p></p><p class="bulletIndent2">For dosing based upon PMA [<a href="#rid24">24</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>PMA 29 to 35 weeks – 15 mg/kg per dose IV every 12 hours</p><p class="bulletIndent3"><span class="glyph">-</span>PMA &gt;35 weeks – 15 mg/kg per dose IV every eight hours</p><p></p><p class="bulletIndent2">Continuous infusion dosing regimens have also been described, but further clinical trials are needed before this method can be employed routinely. Continuous infusion may be associated with earlier attainment of target concentrations and lower total daily dose compared with intermittent dosing [<a href="#rid25">25,26</a>]; however, it is unclear whether this results in more rapid clearance of infection compared with standard dosing. Most studies on continuous <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> infusion have focused on MRSA infections. The importance of achieving a particular vancomycin exposure for successful treatment of coagulase-negative staphylococci infections is not well established.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aminoglycoside </strong>– Dosing depends on postnatal age [<a href="#rid3">3,7,9,20</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For newborns 3 to ≤7 days old, <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> is given as 4 mg/kg per dose IV every 24 hours; <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a> is given as 15 mg/kg per dose IV every 24 hours or 10 mg/kg per dose IV every 12 hours</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For newborns &gt;7 days old, <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> is given as 5 mg/kg per dose IV every 24 hours; <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a> is given as 18 mg/kg per dose IV every 24 hours or 10 mg/kg per dose IV every eight hours</p><p></p><p class="bulletIndent2">Serum <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> or <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a> levels are <strong>not</strong> required if a treatment course of ≤48 hours is anticipated and renal function is normal; however, levels should be obtained in neonates receiving a full course of therapy with an aminoglycoside [<a href="#rid8">8,9</a>].</p><p></p><p class="headingAnchor" id="H943509807"><span class="h3">Coverage for focal sources of infection</span><span class="headingEndMark"> — </span>For neonates with an apparent focal source of infection, the empiric antibiotic regimen is modified as follows  (<a class="graphic graphic_table graphicRef102574" href="/z/d/graphic/102574.html" rel="external">table 4</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected meningitis</strong> – In neonates with late-onset sepsis in whom the lumbar puncture suggests meningitis (eg, CSF pleocytosis), an expanded-spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> [where available], <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>, or <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>) should be substituted for the aminoglycoside in the regimen. This broadens empiric coverage for gram-negative organisms and provides optimal activity in the CSF against pneumococci. If there is concern for meningitis caused by a multidrug-resistant, gram-negative organism, a carbapenem (eg, <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>) is the preferred agent for empiric therapy [<a href="#rid27">27</a>]. Treatment of bacterial meningitis in neonates is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6016.html" rel="external">"Bacterial meningitis in the neonate: Treatment and outcome", section on 'Empiric therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected pneumonia</strong> – Empiric regimens for the treatment of neonates with a pulmonary focus of infection include <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> and an aminoglycoside (<a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> or <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a>), ampicillin and an extended-spectrum cephalosporin, <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> and an extended-spectrum cephalosporin, or vancomycin and an aminoglycoside. Empiric therapy for neonatal pneumonia is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5004.html" rel="external">"Neonatal pneumonia", section on 'Initial empiric therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin, soft tissue, bone, and joint infections</strong> – If there is a focus of infection involving the skin, umbilicus, soft tissues, bone, or joints (in which case, <em>S</em>. <em>aureus</em> is a likely pathogen), <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a>, or <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> should be substituted for <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> [<a href="#rid28">28</a>]. In a toxic-appearing neonate, a semisynthetic penicillin (eg, oxacillin/nafcillin) can be used in combination with vancomycin. (See  <a class="medical medical_review" href="/z/d/html/106447.html" rel="external">"Skin and soft tissue infections in neonates: Evaluation and management", section on 'Antimicrobial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catheter-related infection</strong> – If intravascular catheter-related infection is a concern, treatment should be initiated with <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> and an aminoglycoside to provide empiric coverage for coagulase-negative staphylococci, <em>S</em>. <em>aureus</em>, and gram-negative bacteria. (See  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Empiric antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected intestinal source</strong> – If infection is thought to arise from the gastrointestinal tract, the empiric regimen should include coverage for anaerobic bacteria (eg, with <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>/tazobactam, <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">metronidazole</a>, or <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>). (See  <a class="medical medical_review" href="/z/d/html/5006.html" rel="external">"Neonatal necrotizing enterocolitis: Management and prognosis", section on 'Choice and duration of antibiotic regimen'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Culture-proven sepsis</span><span class="headingEndMark"> — </span>In neonates with culture-proven sepsis, the usual course of therapy is 10 days [<a href="#rid8">8,29</a>]. Longer treatment courses may be warranted if a specific focus of infection is identified (eg, meningitis, osteomyelitis, or septic arthritis). Antimicrobial therapy should be altered based upon the susceptibility profile of the pathogen isolated.</p><p class="headingAnchor" id="H18750256"><span class="h3">Pathogen-specific therapy</span><span class="headingEndMark"> — </span>For the most common causative organisms of neonatal sepsis, antimicrobial therapy is as follows  (<a class="graphic graphic_table graphicRef102574" href="/z/d/graphic/102574.html" rel="external">table 4</a>):</p><p class="headingAnchor" id="H943510209"><span class="h4">Group B Streptococcus</span><span class="headingEndMark"> — </span>The drug of choice for GBS is penicillin. Thus, when GBS is identified and resolution of bacteremia is documented by a repeat blood culture and, in neonates with meningitis, the CSF is sterile, we recommend discontinuing <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> and continuing therapy with <a class="drug drug_pediatric" data-topicid="12687" href="/z/d/drug information/12687.html" rel="external">penicillin G</a> alone  (<a class="graphic graphic_table graphicRef66906" href="/z/d/graphic/66906.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants", section on 'Definitive therapy'</a>.)</p><p class="headingAnchor" id="H943510215"><span class="h4">Escherichia coli</span><span class="headingEndMark"> — </span>In patients with ampicillin-sensitive <em>E</em>. <em>coli</em> sepsis who have improved clinically and in whom meningitis has been excluded, <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> monotherapy is administered for a 10-day course [<a href="#rid27">27</a>].</p><p>For patients with ampicillin-resistant <em>E</em>. <em>coli</em>, the choice of definitive therapy is based upon the susceptibility profile. An expanded-spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> [where available], <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>, or <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>) is often employed if the isolate is susceptible.</p><p class="headingAnchor" id="H943510222"><span class="h4">Other gram-negative bacilli</span><span class="headingEndMark"> — </span>Antimicrobial treatment of infections caused by <em>Klebsiella</em>, <em>Proteus</em>, <em>Enterobacter</em>, <em>Serratia</em>, <em>Pseudomonas</em>, <em>Salmonella</em>, or <em>Shigella</em> should be selected based upon the susceptibility profile of the organism. Single-agent therapy is sufficient in most cases.</p><p>Infections caused by multidrug-resistant, gram-negative bacilli, including those caused by extended-spectrum beta-lactamase-producing organisms or those with hyperproduction of beta-lactamases, should be treated with <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>.</p><p class="headingAnchor" id="H943510228"><span class="h4">Listeria monocytogenes</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> and <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> is used for initial therapy. Treatment with both agents is more effective than ampicillin alone in vitro and in animal models of <em>Listeria</em> infection. Cephalosporins are <strong>not</strong> active against <em>L</em>. <em>monocytogenes</em>. Duration of therapy usually is 10 days. (See  <a class="medical medical_review" href="/z/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection", section on 'Antibiotic therapy'</a>.)</p><p class="headingAnchor" id="H943510235"><span class="h4"><i>Staphylococcus</i> species</span><span class="headingEndMark"> — </span>Directed therapy for infection caused by staphylococci is determined by the sensitivity of the isolate to specific antibiotic agents:</p><p class="bulletIndent1"><span class="glyph">●</span><em>S</em>. <em>aureus</em> – <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">Vancomycin</a> or, in a toxic-appearing neonate, vancomycin plus <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a>, should be employed for <em>S</em>. <em>aureus</em> infection until the susceptibility profile is available. The regimen then should be adjusted according to the susceptibility profile:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MSSA – Treatment of MSSA infection should be completed with <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a> or <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a>. <a class="drug drug_pediatric" data-topicid="13124" href="/z/d/drug information/13124.html" rel="external">Cefazolin</a> is an alternative for treatment of most MSSA infections outside of the central nervous system and not involving endocarditis. (See  <a class="medical medical_review" href="/z/d/html/5967.html" rel="external">"Staphylococcus aureus bacteremia in children: Management and outcome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MRSA – Treatment should be completed with <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>. (See  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'Treatment of neonates'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulase-negative staphylococci – Coagulase-negative staphylococcal infections require treatment with <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>.</p><p></p><p class="headingAnchor" id="H342331"><span class="h2">Probable but unproven sepsis</span><span class="headingEndMark"> — </span>In neonates with a negative blood culture but a clinical status that remains concerning for a systemic infection (eg, ongoing temperature instability; ongoing respiratory, cardiocirculatory, or neurologic findings) not explained by other conditions, antibiotic therapy can be extended for as long as a total of 5 to 10 days.</p><p>After 36 to 48 hours, the empiric regimen is altered based upon whether meningitis has been excluded:</p><p class="bulletIndent1"><span class="glyph">●</span>If meningitis has been excluded, the <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> dosing regimen can be reduced to 100 mg/kg/dose IV every 12 hours in neonates &lt;7 days old or 50 mg/kg/dose IV every six hours in neonates ≥7 days old [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a lumbar puncture has not been performed, <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> should be continued at a meningitic dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of neonates with CSF pleocytosis and/or positive CSF culture is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6016.html" rel="external">"Bacterial meningitis in the neonate: Treatment and outcome"</a>.)</p><p></p><p>Alternative diagnoses should also be entertained when a neonate with suspected sepsis has negative cultures  (<a class="graphic graphic_table graphicRef100409" href="/z/d/graphic/100409.html" rel="external">table 1</a>). Antibiotics should be discontinued if another diagnosis is established. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Infection unlikely</span><span class="headingEndMark"> — </span>Empiric antibiotics are initiated in many neonates with maternal risk factors, abnormal laboratory values, and/or mild to moderate symptoms that subsequently resolve. Sepsis is unlikely in these neonates if they remain well and the blood culture is sterile at 36 to 48 hours. Empiric antibiotic therapy should be discontinued after 36 to 48 hours in these neonates unless there is evidence of site-specific infection [<a href="#rid2">2,30</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Response to therapy</span><span class="headingEndMark"> — </span>In most cases, symptomatic neonates with proven sepsis improve clinically within 24 to 48 hours.</p><p>In neonates with bacteremia, a repeat blood culture should be obtained after 24 to 48 hours of therapy to document sterility. Failure to sterilize the bloodstream suggests that the antimicrobial(s) chosen are not active against the infecting pathogen or that there is an unrecognized focus of infection. Consultation with a pediatric infectious disease specialist may be warranted.</p><p class="headingAnchor" id="H14"><span class="h1">ADJUNCTIVE THERAPIES</span><span class="headingEndMark"> — </span>The following adjunctive immunotherapeutic interventions have been studied in neonatal sepsis but should <strong>not</strong> be routinely administered, because they have not been shown to conclusively improve outcomes [<a href="#rid31">31-33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) infusions [<a href="#rid34">34,35</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Granulocyte transfusions [<a href="#rid36">36</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) [<a href="#rid37">37,38</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12694" href="/z/d/drug information/12694.html" rel="external">Pentoxifylline</a> [<a href="#rid39">39</a>]</p><p></p><p>Most of the studies investigating these therapies involved preterm neonates. These data are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Adjunct therapy to antibiotics'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The primary intervention to prevent neonatal sepsis is the use of intrapartum antibiotic prophylaxis (IAP) in mothers with group B streptococcal (GBS) colonization and other risk factors. Although IAP has resulted in a decrease in the incidence of early-onset GBS invasive neonatal infection, it has not had a similar impact on the rate of late-onset GBS disease. (See  <a class="medical medical_review" href="/z/d/html/438.html" rel="external">"Prevention of early-onset group B streptococcal disease in neonates"</a> and  <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants", section on 'Epidemiology'</a>.)</p><p>Other modifiable risk factors for late-onset sepsis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Indwelling catheters and other devices (eg, central venous catheters, endotracheal tubes, bladder catheters)</p><p class="bulletIndent1"><span class="glyph">●</span>Gastric acid-blocking agents </p><p class="bulletIndent1"><span class="glyph">●</span>Postnatal glucocorticoids </p><p></p><p>Use of these devices and pharmacologic agents should be reassessed often to determine if they can be safely discontinued.</p><p>Comprehensive prevention of neonatal sepsis will require a multi-interventional program including effective maternal vaccination, reduction in preterm delivery, limited exposure of term neonates to potential pathogens, antimicrobial stewardship, and enhanced infection control and prevention techniques.</p><p>Probiotics and lactoferrin have been investigated as potential preventative interventions in preterm neonates [<a href="#rid40">40,41</a>]; however, neither approach has been conclusively proven to reduce the risk of sepsis, and these interventions are not routinely used in clinical practice. These data are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Potential prophylactic therapy'</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Overall mortality in term and late preterm neonates with neonatal sepsis is approximately 2 to 3 percent [<a href="#rid15">15,42</a>]. Mortality estimates vary depending on the gestational age (lower gestational age is associated with higher mortality), pathogen (gram-negative pathogens are associated with higher mortality than gram-positive infections), and sepsis definition (lower mortality rates tend to be reported in studies including neonates with both culture-positive and culture-negative clinical sepsis compared with studies limited only to neonates with culture-proven sepsis).</p><p>Mortality rates for group B streptococcal (GBS) sepsis in term neonates after the introduction of intrapartum antibiotic prophylaxis (IAP) and routine use of empirical antibiotic therapy range from 2 to 3 percent for early-onset disease and 1 to 2 percent for late-onset disease. Outcomes for infants with GBS infection are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants", section on 'Outcome'</a>.)</p><p>The risk of mortality is particularly high in neonates with <em>E</em>. <em>coli</em> sepsis. Estimated mortality rates for term neonates with <em>E</em>. <em>coli</em> sepsis are 5 to 10 percent [<a href="#rid10">10,43-45</a>].</p><p class="headingAnchor" id="H2672443870"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110817.html" rel="external">"Society guideline links: Sepsis in neonates"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112235.html" rel="external">"Society guideline links: Group B streptococcal infection in pregnant women and neonates"</a>.)</p><p class="headingAnchor" id="H164795296"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17189.html" rel="external">"Patient education: Sepsis in newborn babies (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance</strong> – Although the incidence of sepsis in term and late preterm neonates is low, the potential for serious adverse outcomes, including death, is of such great consequence that care providers should have a low threshold for evaluation and treatment for possible sepsis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Symptomatic neonates should be treated in a care setting with full cardiopulmonary monitoring and support because neonates with sepsis can deteriorate rapidly. Supportive care includes (see <a class="local">'Supportive care'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maintaining adequate oxygenation and perfusion (see  <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">"Respiratory support, oxygen delivery, and oxygen monitoring in the newborn"</a> and  <a class="medical medical_review" href="/z/d/html/126605.html" rel="external">"Neonatal shock: Management"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Prevention of hypoglycemia and metabolic acidosis (see  <a class="medical medical_review" href="/z/d/html/101425.html" rel="external">"Management and outcome of neonatal hypoglycemia"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Maintenance of normal fluid and electrolyte status (see  <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antibiotic therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – Indications for empiric antibiotic therapy include any of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Ill appearance (see  <a class="medical medical_review" href="/z/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)"</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Concerning symptoms (eg, temperature instability or respiratory, cardiocirculatory, or neurologic symptoms) (see  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Early-onset sepsis calculator'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>High estimated risk of early-onset sepsis based on a validated risk <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fneonatalsepsiscalculator.kaiserpermanente.org%2F&amp;token=onMkmNxqZshoDc22JN8OR%2BQKCg7t0pcaNNq2h8esYG515dR4JaAxDq9tt4oaRDV5Qc%2FbUukpm4cZ872Q8bCopQ%3D%3D&amp;TOPIC_ID=5046" target="_blank">calculator</a> (see  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Early-onset sepsis calculator'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cerebrospinal fluid (CSF) pleocytosis (white blood cell count of &gt;20 to 30 cells/microL)  (<a class="graphic graphic_table graphicRef54464" href="/z/d/graphic/54464.html" rel="external">table 3</a>) (see  <a class="medical medical_review" href="/z/d/html/6005.html" rel="external">"Bacterial meningitis in the neonate: Clinical features and diagnosis", section on 'Interpretation of cerebrospinal fluid'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Positive blood, urine, or CSF culture (see  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Blood culture'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empiric regimen</strong> – Empiric antibiotic therapy for neonates with suspected sepsis should provide broad coverage for the most likely pathogens (group B <em>Streptococcus</em> [GBS] and gram-negative enteric organisms, including <em>Escherichia</em> <em>coli</em>)  (<a class="graphic graphic_table graphicRef61061" href="/z/d/graphic/61061.html" rel="external">table 5</a>). Our suggested approach is as follows  (<a class="graphic graphic_table graphicRef102574" href="/z/d/graphic/102574.html" rel="external">table 4</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For neonates with <strong>early-onset sepsis</strong> (ie, within first 72 hours after birth) without an apparent focus, we suggest initial empiric therapy with <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> plus an aminoglycoside (<a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> or <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a>, depending on local antibiotic susceptibility patterns) rather than other agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Early-onset sepsis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For neonates with <strong>late-onset sepsis</strong> (ie, at ≥72 hours after birth) without an apparent focus who are <strong>admitted from the community</strong>, we also suggest <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> plus an aminoglycoside rather than other agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A reasonable alternative is ampicillin plus and extended spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> [if available], <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>, or <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>). (See <a class="local">'Late-onset sepsis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For neonates with <strong>late-onset sepsis</strong> without an apparent focus who continue to be <strong>hospitalized from birth</strong>, we suggest <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> plus an aminoglycoside rather than other agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A regimen of <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a> or <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> plus an aminoglycoside is a reasonable alternative if the neonate is not critically ill and has a recent negative methicillin-resistant <em>Staphylococcus</em> <em>aureus</em> (MRSA) screening test. (See <a class="local">'Late-onset sepsis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Focal infections</strong> – For neonates with an apparent focal source of infection, the empiric antibiotic regimen is modified as summarized in the table  (<a class="graphic graphic_table graphicRef102574" href="/z/d/graphic/102574.html" rel="external">table 4</a>) and discussed separately (see <a class="local">'Coverage for focal sources of infection'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Meningitis (see  <a class="medical medical_review" href="/z/d/html/6016.html" rel="external">"Bacterial meningitis in the neonate: Treatment and outcome", section on 'Empiric therapy'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Pneumonia (see  <a class="medical medical_review" href="/z/d/html/5004.html" rel="external">"Neonatal pneumonia", section on 'Initial empiric therapy'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Infections involving the skin, soft tissues, bone, or joints (ie, suspected <em>S. aureus</em> infection) (see  <a class="medical medical_review" href="/z/d/html/106447.html" rel="external">"Skin and soft tissue infections in neonates: Evaluation and management", section on 'Choice of initial therapy'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Intravascular catheter-related infection (see  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Empiric antibiotic therapy'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Intestinal source (see  <a class="medical medical_review" href="/z/d/html/5006.html" rel="external">"Neonatal necrotizing enterocolitis: Management and prognosis", section on 'Choice and duration of antibiotic regimen'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitive therapy</strong> – Antibiotic therapy is altered based upon isolation of the causative agent and its antimicrobial susceptibility pattern. (See <a class="local">'Pathogen-specific therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to therapy</strong> – Most neonates with culture-proven sepsis improve clinically within 24 to 48 hours after starting appropriate antibiotic treatment. The response to antibiotic therapy is assessed by a repeat blood culture 24 to 48 hours after initiation of antibiotic therapy. Failure to sterilize the bloodstream suggests either that the antimicrobial(s) chosen are not active against the infecting pathogen or that there is an unrecognized focus of infection. (See <a class="local">'Response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – In neonates with culture-proven sepsis, the usual course of therapy is 10 days. Longer treatment is warranted if a specific focus of infection is identified (eg, meningitis, osteomyelitis, or septic arthritis). (See <a class="local">'Culture-proven sepsis'</a> above.)</p><p></p><p class="bulletIndent1">In well-appearing neonates with negative cultures after 36 to 48 hours, empiric antibiotic therapy should be discontinued since sepsis is unlikely in these neonates. (See <a class="local">'Infection unlikely'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – The mortality associated with neonatal sepsis in term neonates is &lt;5 percent. The risk varies depending on gestational age (lower gestational age is associated with higher mortality) and pathogen (gram-negative pathogens are associated with higher mortality than gram-positive infections). (See <a class="local">'Outcome'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Raju TN, Higgins RD, Stark AR, Leveno KJ. Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. Pediatrics 2006; 118:1207.</a></li><li><a class="nounderline abstract_t">Puopolo KM, Benitz WE, Zaoutis TE, et al. Management of Neonates Born at ≥35 0/7 Weeks' Gestation With Suspected or Proven Early-Onset Bacterial Sepsis. Pediatrics 2018; 142.</a></li><li class="breakAll">American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2021 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.707.</li><li><a class="nounderline abstract_t">Jefferies AL. Management of term infants at increased risk for early-onset bacterial sepsis. Paediatr Child Health 2017; 22:223.</a></li><li class="breakAll">Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious diseases of the Fetus and Newborn Infant, 8th ed, Remington JS, et al (Eds), Elsevier Saunders, Philadelphia 2016. p.217.</li><li><a class="nounderline abstract_t">Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.</a></li><li class="breakAll">American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.876.</li><li class="breakAll">Edwards, MS, Baker, CJ. Sepsis in the Newborn. In: Krugman's Infectious Diseases of Children, 11th ed, Gershon, AA, Hotez, PJ, Katz, SL (Eds), Mosby, Philadelphia 2004, p. 545.</li><li><a class="nounderline abstract_t">Rao SC, Srinivasjois R, Moon K. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2016; 12:CD005091.</a></li><li><a class="nounderline abstract_t">Stoll BJ, Hansen NI, Sánchez PJ, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011; 127:817.</a></li><li><a class="nounderline abstract_t">Muller-Pebody B, Johnson AP, Heath PT, et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed 2011; 96:F4.</a></li><li><a class="nounderline abstract_t">Maayan-Metzger A, Barzilai A, Keller N, Kuint J. Are the "good old" antibiotics still appropriate for early-onset neonatal sepsis? A 10 year survey. Isr Med Assoc J 2009; 11:138.</a></li><li><a class="nounderline abstract_t">Stoll BJ, Puopolo KM, Hansen NI, et al. Early-Onset Neonatal Sepsis 2015 to 2017, the Rise of Escherichia coli, and the Need for Novel Prevention Strategies. JAMA Pediatr 2020; 174:e200593.</a></li><li><a class="nounderline abstract_t">Flannery DD, Puopolo KM, Hansen NI, et al. Antimicrobial Susceptibility Profiles Among Neonatal Early-onset Sepsis Pathogens. Pediatr Infect Dis J 2022; 41:263.</a></li><li><a class="nounderline abstract_t">Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006; 117:67.</a></li><li><a class="nounderline abstract_t">Bryan CS, John JF Jr, Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Am J Dis Child 1985; 139:1086.</a></li><li><a class="nounderline abstract_t">Gulian JM, Dalmasso C, Gonard V. Interaction of beta-lactam antibiotics on bilirubin-albumin complex: comparison by three methods, total bilirubin, unbound bilirubin and erythrocyte-bound bilirubin. Chemotherapy 1990; 36:91.</a></li><li><a class="nounderline abstract_t">Martin E, Fanconi S, Kälin P, et al. Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr 1993; 152:530.</a></li><li><a class="nounderline abstract_t">Pantell RH, Roberts KB, Adams WG, et al. Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old. Pediatrics 2021; 148.</a></li><li class="breakAll">Toy C. Medications. In: Guidelines for acute care of the neonate, 30, Fernandes CJ, Pammi M, Katakam L (Eds), Guidelines for acute care of the neonate, Houston, TX 2022-2023. p.300.</li><li><a class="nounderline abstract_t">Korang SK, Safi S, Nava C, et al. Antibiotic regimens for late-onset neonatal sepsis. Cochrane Database Syst Rev 2021; 5:CD013836.</a></li><li><a class="nounderline abstract_t">Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 2011; 11:279.</a></li><li><a class="nounderline abstract_t">Chiu CH, Michelow IC, Cronin J, et al. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit. Pediatr Infect Dis J 2011; 30:273.</a></li><li><a class="nounderline abstract_t">Hill LF, Clements MN, Turner MA, et al. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. Lancet Child Adolesc Health 2022; 6:49.</a></li><li><a class="nounderline abstract_t">Gwee A, Cranswick N, McMullan B, et al. Continuous Versus Intermittent Vancomycin Infusions in Infants: A Randomized Controlled Trial. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Plan O, Cambonie G, Barbotte E, et al. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule. Arch Dis Child Fetal Neonatal Ed 2008; 93:F418.</a></li><li class="breakAll">American Academy of Pediatrics. Serious neonatal bacterial infections caused by Enterobacteriaceae (including septicemia and meningitis). In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd Ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.311.</li><li><a class="nounderline abstract_t">Fortunov RM, Hulten KG, Hammerman WA, et al. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics 2006; 118:874.</a></li><li class="breakAll">Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant, 8th ed, Wilson C, Nizet V, Maldonado Y, et al (Eds), Elsevier, 2014. p.217.</li><li><a class="nounderline abstract_t">Polin RA, Watterberg K, Benitz W, Eichenwald E. The conundrum of early-onset sepsis. Pediatrics 2014; 133:1122.</a></li><li class="breakAll">Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, et al (Eds), WB Saunders, Philadelphia 2010. p.222.</li><li><a class="nounderline abstract_t">Gerdes JS. Diagnosis and management of bacterial infections in the neonate. Pediatr Clin North Am 2004; 51:939.</a></li><li><a class="nounderline abstract_t">Cohen-Wolkowiez M, Benjamin DK Jr, Capparelli E. Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. Curr Opin Pediatr 2009; 21:177.</a></li><li><a class="nounderline abstract_t">INIS Collaborative Group, Brocklehurst P, Farrell B, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011; 365:1201.</a></li><li><a class="nounderline abstract_t">Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev 2015; :CD001239.</a></li><li><a class="nounderline abstract_t">Pammi M, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev 2011; :CD003956.</a></li><li><a class="nounderline abstract_t">Schibler KR, Osborne KA, Leung LY, et al. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998; 102:6.</a></li><li><a class="nounderline abstract_t">Carr R, Modi N, Doré C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003; :CD003066.</a></li><li><a class="nounderline abstract_t">Pammi M, Haque KN. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 2015; :CD004205.</a></li><li><a class="nounderline abstract_t">Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2020; 3:CD007137.</a></li><li><a class="nounderline abstract_t">Rao SC, Athalye-Jape GK, Deshpande GC, et al. Probiotic Supplementation and Late-Onset Sepsis in Preterm Infants: A Meta-analysis. Pediatrics 2016; 137:e20153684.</a></li><li><a class="nounderline abstract_t">Schrag SJ, Farley MM, Petit S, et al. Epidemiology of Invasive Early-Onset Neonatal Sepsis, 2005 to 2014. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011; 30:937.</a></li><li><a class="nounderline abstract_t">Escobar GJ, Li DK, Armstrong MA, et al. Neonatal sepsis workups in infants &gt;/=2000 grams at birth: A population-based study. Pediatrics 2000; 106:256.</a></li><li><a class="nounderline abstract_t">Bergin SP, Thaden JT, Ericson JE, et al. Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy. Pediatr Infect Dis J 2015; 34:933.</a></li></ol></div><div id="topicVersionRevision">Topic 5046 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951017" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30455342" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of Neonates Born at≥35 0/7 Weeks' Gestation With Suspected or Proven Early-Onset Bacterial Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30455342" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of Neonates Born at≥35 0/7 Weeks' Gestation With Suspected or Proven Early-Onset Bacterial Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29480905" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of term infants at increased risk for early-onset bacterial sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29480905" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of term infants at increased risk for early-onset bacterial sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088663" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088663" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088663" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27921299" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21518717" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584804" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Empirical treatment of neonatal sepsis: are the current guidelines adequate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19544701" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Are the "good old" antibiotics still appropriate for early-onset neonatal sepsis? A 10 year survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32364598" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Early-Onset Neonatal Sepsis 2015 to 2017, the Rise of Escherichia coli, and the Need for Novel Prevention Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34862339" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antimicrobial Susceptibility Profiles Among Neonatal Early-onset Sepsis Pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396862" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3904403" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2311445" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interaction of beta-lactam antibiotics on bilirubin-albumin complex: comparison by three methods, total bilirubin, unbound bilirubin and erythrocyte-bound bilirubin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8335024" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34281996" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34281996" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33998665" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antibiotic regimens for late-onset neonatal sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22011388" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21085051" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34843669" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30700564" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Continuous Versus Intermittent Vancomycin Infusions in Infants: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450803" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450803" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950976" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950976" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24799547" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The conundrum of early-onset sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24799547" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The conundrum of early-onset sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15275982" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnosis and management of bacterial infections in the neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19276977" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21962214" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of neonatal sepsis with intravenous immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25815707" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intravenous immunoglobulin for suspected or proven infection in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975741" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9651406" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917944" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : G-CSF and GM-CSF for treating or preventing neonatal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25751631" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32232984" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908700" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Probiotic Supplementation and Late-Onset Sepsis in Preterm Infants: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940705" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Epidemiology of Invasive Early-Onset Neonatal Sepsis, 2005 to 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21654548" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10920148" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neonatal sepsis workups in infants&gt;/=2000 grams at birth: A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26065862" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
